Arrivent Biopharma earnings were -$127.5M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest AVBP earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$64.4M, up 212.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AVBP reported annual earnings of -$80.5M, with 16.1% growth.
What were Arrivent Biopharma's earnings last quarter?
Arrivent Biopharma (NASDAQ: AVBP) reported Q1 2025 earnings per share (EPS) of -$1.90, up 171.43% year over year. Total AVBP earnings for the quarter were -$64.39 million. In the same quarter last year, Arrivent Biopharma's earnings per share (EPS) was -$0.70.
As of the last Arrivent Biopharma earnings report, Arrivent Biopharma is currently losing money. Arrivent Biopharma's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$127.46 million, a 70.91% increase year over year.
What was AVBP's earnings growth in the past year?
As of Arrivent Biopharma's earnings date in Q2 2025, Arrivent Biopharma's earnings has grown year over year. AVBP earnings in the past year totalled -$127.46 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.